Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen
Amgen
Ain Shams University
Pfizer
Medical College of Wisconsin
Pfizer
ChineseAMS
Novartis
Singapore Eye Research Institute
Peking University People's Hospital
Indonesia University
University of Maryland, Baltimore
Swiss Pediatric Oncology Group
Children's Hospital of Michigan
Cytovia, Inc.
University of Kansas Medical Center
Novartis
Novartis
Chinese PLA General Hospital
Rabin Medical Center
Fox Chase Cancer Center
Novartis
Sun Yat-sen University
Federal University of Minas Gerais
Pfizer
PETHEMA Foundation
Sanofi
East Valley Hematology and Oncology Medical Group